Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess the effect of IMEG on the pharmacokinetic (PK) profile of Metformin (MET) following repeated co-administration in healthy subjects

Next Previous
Trial Profile

To assess the effect of IMEG on the pharmacokinetic (PK) profile of Metformin (MET) following repeated co-administration in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imeglimin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms MET-IMEG DDI

Most Recent Events

  • 16 Apr 2020 New trial record
  • 09 Apr 2020 According to results published in the Clinical Pharmacokinetics, this study was conducted by Parexel International GmbH.
  • 09 Apr 2020 Results published in the Clinical Pharmacokinetics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top